Anavex Life Sciences Receives FDA Feedback on Alzheimer’s Disease Program
Anavex Life Sciences Receives FDA Feedback on Alzheimer's Disease Program GlobeNewswire January 06, 2026 NEW YORK, Jan. 06, 2026 (GLOBE NEWSWIRE) — Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, […]